Wells Fargo & Company Lowers WAVE Life Sciences (NASDAQ:WVE) Price Target to $13.00

WAVE Life Sciences (NASDAQ:WVE) had its price target reduced by analysts at Wells Fargo & Company from $27.00 to $13.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 104.40% from the stock’s previous close.

A number of other research analysts have also recently issued reports on WVE. Cantor Fitzgerald lifted their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Morgan Stanley set a $28.00 target price on shares of WAVE Life Sciences in a research report on Monday, December 8th. Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $9.00 to $27.00 in a report on Monday, December 8th. Mizuho upped their price objective on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Oppenheimer raised their price objective on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.38.

WAVE Life Sciences Trading Up 2.6%

WVE stock opened at $6.36 on Friday. WAVE Life Sciences has a 1-year low of $5.02 and a 1-year high of $21.73. The business’s 50 day moving average is $12.93 and its 200-day moving average is $11.22. The firm has a market cap of $1.20 billion, a P/E ratio of -5.21 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last posted its earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). The company had revenue of $17.25 million for the quarter, compared to the consensus estimate of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. Sell-side analysts forecast that WAVE Life Sciences will post -1.14 EPS for the current year.

Insiders Place Their Bets

In other WAVE Life Sciences news, insider Chandra Vargeese sold 3,228 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $43,416.60. Following the sale, the insider owned 408,246 shares of the company’s stock, valued at $5,490,908.70. This represents a 0.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kyle Moran sold 3,588 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the completion of the transaction, the chief financial officer directly owned 134,385 shares of the company’s stock, valued at approximately $1,807,478.25. This represents a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 61,748 shares of company stock valued at $907,809. 23.98% of the stock is owned by corporate insiders.

Institutional Trading of WAVE Life Sciences

Hedge funds have recently modified their holdings of the stock. GSK plc bought a new position in WAVE Life Sciences in the 4th quarter worth approximately $310,177,000. Adage Capital Partners GP L.L.C. boosted its position in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after buying an additional 2,500,000 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in WAVE Life Sciences by 83.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after buying an additional 3,362,880 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of WAVE Life Sciences in the 4th quarter valued at $125,168,000. Finally, Federated Hermes Inc. increased its stake in shares of WAVE Life Sciences by 26.5% in the 4th quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock valued at $80,657,000 after buying an additional 993,827 shares during the period. 89.73% of the stock is owned by institutional investors.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.